Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ZIOPHARM to Present at the Stifel 2017 Healthcare Conference
BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.
View HTML
Toggle Summary ZIOPHARM Oncology Reports Third Quarter 2017 Financial Results and Provides Update on Recent Activities
Company to host conference call today at 4:30 p.m. ET Pivotal, randomized control trial in rGBM to initiate by end of 2017 Combination trial with checkpoint inhibitor in rGBM to initiate by end of 2017 Point-of-care trial with CAR + T cells co-expressing membrane-bound interleukin (mbIL15) to
View HTML
Toggle Summary ZIOPHARM Announces Four Presentation Abstracts at the 2017 Annual Meeting of the Society for Neuro-Oncology
- Update to survival data from Phase 1 Trial of Ad-RTS-hIL-12 to treat recurrent glioblastoma (GBM) to be presented - - Additional biomarker and biopsy data provides evidence of IL-12 driving immune response to GBM - BOSTON, Nov. 06, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc.
View HTML
Toggle Summary ZIOPHARM Announces Five Abstracts Accepted for Presentation at the 2017 American Society of Hematology Annual Meeting
BOSTON, Nov. 01, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that five abstracts highlighting data from the Company's adoptive cell-based therapeutic programs have
View HTML
Toggle Summary ZIOPHARM Oncology to Host Third-Quarter 2017 Financial Results and Corporate Update Conference Call on November 6, 2017 at 4:30 p.m. ET
BOSTON, Oct. 26, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that it will host a conference call and webcast slide presentation on Monday, November 6, 2017 at 4:30 p.m.
View HTML
Toggle Summary A Virus, a Gene and a Pill Used to Harness the Immune System to Fight Brain Tumor in Children
  ZIOPHARM Oncology is pleased to share a story from the Ann & Robert H. Lurie Children's Hospital in Chicago on the Ad-RTS-hIL-12 plus veledimex clinical trial for pediatric patients with brain cancer. As we announced last week, Stewart Goldman, M.D., Division Head Hematology-Oncology,
View HTML
Toggle Summary ZIOPHARM Oncology Announces First Patient Dosed in New Phase 1 Study of Ad-RTS-hIL-12 plus Veledimex for the Treatment of Pediatric Brain Tumors
BOSTON, Oct. 16, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company developing new gene and cell-based immunotherapies for cancer, today announced that the first patient has been dosed in a new Phase 1 study of Ad-RTS-hIL-12 with veledimex for the treatment
View HTML
Toggle Summary ZIOPHARM Announces Three Presentations at the 2017 Annual Meeting of the Society for Neuro-Oncology
BOSTON, Oct. 12, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on developing gene and cell-based immunotherapies for cancer, today announced that three abstracts highlighting data from the Company's Ad-RTS-hIL-12 + veledimex program have been
View HTML
Toggle Summary ZIOPHARM Oncology Appoints David Mauney, M.D., as Executive Vice President and Chief Business Officer
BOSTON, Sept. 28, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focusing on new immunotherapies, announces the appointment of David Mauney, M.D., as Executive Vice President and Chief Business Officer, effective today.  ZIOPHARM also reports the details
View HTML
Toggle Summary ZIOPHARM Oncology Announces Updated Findings from Phase 1 Study of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at American Academy of Neurological Surgery Annual Meeting
BOSTON, Sept. 18, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that updated data from a subset of patients in its Phase 1 multicenter study of Ad-RTS-hIL-12 + veledimex in patients with recurrent or
View HTML